Chippenham-based specialty pharmaceutical firm Alliance Parma has appointed Andrew Franklin as finance director. Andrew, pictured, joins the company in September 28 from Panasonic Europe, where he was general manager, European tax and accounting.
From 2010 to 2012 he was finance director and company secretary of Genzyme Therapeutics, the UK & Ireland subsidiary of Genzyme Corporation, the biotechnology company acquired by Sanofi. 
Prior to that he gained 12 years’ pharmaceutical experience with Wyeth in a variety of senior financial positions. He qualified as a chartered accountant with Arthur Andersen in 1992 having graduated in 1988 with a first-class degree in civil engineering from University of Wales, Cardiff.
He replaces Richard Wright, who had been Alliance’s finance director for nearly eight years,
Alliance chief executive officer John Dawson said: “Andrew brings considerable experience, having operated for 14 years in senior financial roles in the pharmaceutical industry. Andrew will be a strong addition to the Alliance team.”
Alliance, which is listed on the London Stock Exchange, specialises in buying underperforming drugs brands and realises their potential through investment.
